1. Cancer Biology
Download icon

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer

  1. Laura Cato
  2. Antje Neeb
  3. Adam Sharp
  4. Victor Buzón
  5. Scott B Ficarro
  6. Linxiao Yang
  7. Claudia Muhle-Goll
  8. Nane C Kuznik
  9. Ruth Riisnaes
  10. Daniel Nava Rodrigues
  11. Olivier Armant
  12. Victor Gourain
  13. Guillaume Adelmant
  14. Emmanuel A Ntim
  15. Thomas Westerling
  16. David Dolling
  17. Pasquale Rescigno
  18. Ines Figueiredo
  19. Friedrich Fauser
  20. Jennifer Wu
  21. Jaice T Rottenberg
  22. Liubov Shatkina
  23. Claudia Ester
  24. Burkhard Luy
  25. Holger Puchta
  26. Jakob Troppmair
  27. Nicole Jung
  28. Stefan Bräse
  29. Uwe Strähle
  30. Jarrod A Marto
  31. Gerd Ulrich Nienhaus
  32. Bissan Al-Lazikani
  33. Xavier Salvatella
  34. Johann S de Bono
  35. Andrew CB Cato  Is a corresponding author
  36. Myles Brown  Is a corresponding author
  1. Dana-Farber Cancer Institute, United States
  2. Institute of Cancer Research, United Kingdom
  3. The Barcelona Institute of Science and Technology, Spain
  4. Karlsruhe Institute of Technology, Germany
  5. Innsbruck Medical University, Austria
  6. The Institute of Cancer Research, United Kingdom
  7. Dana-Farber Cancer Instittue, United States
Research Article
  • Cited 11
  • Views 2,171
  • Annotations
Cite this article as: eLife 2017;6:e27159 doi: 10.7554/eLife.27159

Abstract

Targeting the activation function-1 (AF-1) domain located in the N-terminus of the androgen receptor (AR) is an attractive therapeutic alternative to the current approaches to inhibit AR action in prostate cancer (PCa). Here we show that the AR AF-1 is bound by the cochaperone Bag-1L. Mutations in the AR interaction domain or loss of Bag-1L abrogate AR signaling and reduce PCa growth. Clinically, Bag-1L protein levels increase with progression to castration-resistant PCa (CRPC) and high levels of Bag-1L in primary PCa associate with a reduced clinical benefit from abiraterone when these tumors progress. Intriguingly, residues in Bag-1L important for its interaction with the AR AF-1 are within a potentially druggable pocket, implicating Bag-1L as a potential therapeutic target in PCa.

Article and author information

Author details

  1. Laura Cato

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7072-4368
  2. Antje Neeb

    Prostate Cancer Target Therapy Group, Institute of Cancer Research, Sutton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Adam Sharp

    Prostate Cancer Target Therapy Group, Institute of Cancer Research, Sutton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Victor Buzón

    Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  5. Scott B Ficarro

    Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Linxiao Yang

    Institute of Applied Physics, Karlsruhe Institute of Technology, Karlsruhe, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Claudia Muhle-Goll

    Institute for Biological Interfaces 4, Karlsruhe Institute of Technology, Karlsruhe, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Nane C Kuznik

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Ruth Riisnaes

    Prostate Cancer Target Therapy Group, Institute of Cancer Research, Sutton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Daniel Nava Rodrigues

    Prostate Cancer Target Therapy Group, Institute of Cancer Research, Sutton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Olivier Armant

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Victor Gourain

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Guillaume Adelmant

    The Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Emmanuel A Ntim

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Thomas Westerling

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. David Dolling

    Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Pasquale Rescigno

    Prostate Cancer Target Therapy Group, Institute of Cancer Research, Sutton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  18. Ines Figueiredo

    Prostate Cancer Target Therapy Group, Institute of Cancer Research, Sutton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  19. Friedrich Fauser

    Botanical Institute II, Karlsruhe Institute of Technology, Karlsruhe, Germany
    Competing interests
    The authors declare that no competing interests exist.
  20. Jennifer Wu

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  21. Jaice T Rottenberg

    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  22. Liubov Shatkina

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  23. Claudia Ester

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  24. Burkhard Luy

    Institute for Biological Interfaces 4, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  25. Holger Puchta

    Botanical Institute II, Karlsruhe Institute of Technology, Karlsruhe, Germany
    Competing interests
    The authors declare that no competing interests exist.
  26. Jakob Troppmair

    Daniel-Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria
    Competing interests
    The authors declare that no competing interests exist.
  27. Nicole Jung

    Institute of Organic Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany
    Competing interests
    The authors declare that no competing interests exist.
  28. Stefan Bräse

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  29. Uwe Strähle

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
  30. Jarrod A Marto

    The Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  31. Gerd Ulrich Nienhaus

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5027-3192
  32. Bissan Al-Lazikani

    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  33. Xavier Salvatella

    Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8371-4185
  34. Johann S de Bono

    Prostate Cancer Target Therapy Group, Institute of Cancer Research, Sutton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  35. Andrew CB Cato

    Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany
    For correspondence
    andrew.cato@kit.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8508-3834
  36. Myles Brown

    Department of Medical Oncology, Dana-Farber Cancer Instittue, Boston, United States
    For correspondence
    myles_brown@dfci.harvard.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8213-1658

Funding

Prostate Cancer Foundation

  • Laura Cato
  • Adam Sharp
  • Johann S de Bono
  • Andrew CB Cato
  • Myles Brown

Deutsche Krebshilfe

  • Andrew CB Cato

Barr Foundation

  • Laura Cato

Prostate Cancer UK

  • Adam Sharp

Medical Research Council

  • Adam Sharp

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Chi Van Dang, University of Pennsylvania, United States

Publication history

  1. Received: March 23, 2017
  2. Accepted: August 7, 2017
  3. Accepted Manuscript published: August 10, 2017 (version 1)
  4. Version of Record published: October 5, 2017 (version 2)

Copyright

© 2017, Cato et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,171
    Page views
  • 480
    Downloads
  • 11
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Cancer Biology
    2. Cell Biology
    Shima Ghoroghi et al.
    Research Article Updated

    Cancer extracellular vesicles (EVs) shuttle at distance and fertilize pre-metastatic niches facilitating subsequent seeding by tumor cells. However, the link between EV secretion mechanisms and their capacity to form pre-metastatic niches remains obscure. Using mouse models, we show that GTPases of the Ral family control, through the phospholipase D1, multi-vesicular bodies homeostasis and tune the biogenesis and secretion of pro-metastatic EVs. Importantly, EVs from RalA or RalB depleted cells have limited organotropic capacities in vivoand are less efficient in promoting metastasis. RalA and RalB reduce the EV levels of the adhesion molecule MCAM/CD146, which favors EV-mediated metastasis by allowing EVs targeting to the lungs. Finally, RalA, RalB, and MCAM/CD146, are factors of poor prognosis in breast cancer patients. Altogether, our study identifies RalGTPases as central molecules linking the mechanisms of EVs secretion and cargo loading to their capacity to disseminate and induce pre-metastatic niches in a CD146-dependent manner.

    1. Biochemistry and Chemical Biology
    2. Cancer Biology
    Lavanya H Palavalli Parsons et al.
    Research Article

    PARP-7 (TiPARP) is a mono(ADP-ribosyl) transferase whose proteins substrates and biological activities are poorly understood. We observed that PARP7 mRNA levels are lower in ovarian cancer patient samples compared to non-cancerous tissue, but PARP-7 protein nonetheless contributes to several cancer-related biological endpoints in ovarian cancer cells (e.g., growth, migration). Global gene expression analyses in ovarian cancer cells subjected to PARP-7 depletion indicate biological roles for PARP-7 in cell-cell adhesion and gene regulation. To identify the MARylated substrates of PARP-7 in ovarian cancer cells, we developed an NAD+ analog-sensitive approach, which we coupled with mass spectrometry to identify the PARP-7 ADP-ribosylated proteome in ovarian cancer cells, including cell-cell adhesion and cytoskeletal proteins. Specifically, we found that PARP-7 MARylates α-tubulin to promote microtubule instability, which may regulate ovarian cancer cell growth and motility. In sum, we identified an extensive PARP-7 ADP-ribosylated proteome with important roles in cancer-related cellular phenotypes.